ASEAN Point of Care Diagnostics Market - Forecast to 2030
商品番号 : SMB-8956
| 出版社 | MarketsandMarkets |
| 出版年月 | 2025年5月 |
| ページ数 | 334 |
| 図表数 | 319 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
この調査レポートでは、ASEANのPOC診断市場を製品別（感染症検査製品、血糖値モニタリング製品、心血管代謝検査製品、凝固モニタリング製品、妊娠・妊孕性検査製品、尿検査製品、がんマーカー検査製品、コレステロール検査製品、血液学検査製品、便潜血検査製品、乱用薬物検査製品、その他POC製品）、技術別（ラテラルフローアッセイ（免疫測定）、迅速検査（分子診断）、生化学）、エンドユーザー別（臨床検査室、病院および救命救急センター、外来診療所および外来診療センター、在宅ケア施設、その他エンドユーザー）、国別（ベトナム、ラオス、カンボジア、マレーシア、ミャンマー、フィリピン、シンガポール、タイ、インドネシア、ブルネイ）に分類しています。レポートは、ASEANのPOC診断市場の成長に影響を与える主要要因（促進要因、抑制要因、機会、課題など）に関する包括的な情報を提供しています。本レポートでは、主要業界プレーヤーの詳細な分析を掲載し、事業概要、ソリューション、主要戦略、買収、契約に関する洞察を提供しています。さらに、新製品・新サービスの発売、そしてポイントオブケア診断市場の最新動向についても解説しています。さらに、ASEANのポイントオブケア診断エコシステムにおける新興スタートアップ企業の競合分析も含まれています。
The ASEAN point of care diagnostics market is expected to grow from USD 1.08 billion in 2025 to reach USD 1.36 billion in 2030, at a CAGR of 4.7% during the forecast period.
ASEANのポイントオブケア診断市場は、予測期間中に4.7%のCAGRで成長し、2025年の10億8,000万米ドルから2030年には13億6,000万米ドルに達すると予想されています。
Favorable government policies and funding investments drive the demand for Point of Care (POC) testing in the ASEAN region. Governments in these countries are increasingly supporting adopting such technologies to improve health access, reduce costs, and enhance patient outcomes. Through strategic partnerships, research initiatives, and nationwide screening campaigns, ASEAN governments promote using POC technologies to make healthcare accessible, lower costs, and improve patient outcomes. In several developing nations within the region, where health infrastructure is relatively underdeveloped, authorities encourage using POC devices to decentralize laboratory-based diagnostics and expand access to testing. These supportive initiatives are fostering the growth of POC diagnostics and creating new market opportunities for diagnostic firms in the ASEAN region.
ASEAN地域におけるPOC（Point of Care）検査の需要は、政府の好ましい政策と資金投資によって牽引されています。これらの国々の政府は、医療へのアクセス向上、コスト削減、そして患者アウトカムの向上を目指し、こうした技術の導入をますます支援しています。ASEAN諸国政府は、戦略的パートナーシップ、研究イニシアチブ、そして全国規模のスクリーニングキャンペーンを通じて、POC技術の活用を促進し、医療へのアクセス向上、コスト削減、そして患者アウトカムの向上を目指しています。医療インフラが比較的未整備なASEAN地域の発展途上国では、当局がPOC機器の活用を奨励し、臨床検査による診断を分散化し、検査へのアクセスを拡大しています。こうした支援策はPOC診断の成長を促進し、ASEAN地域の診断企業にとって新たな市場機会を創出しています。
“The infectious disease testing products segment is expected to register the highest growth rate in the ASEAN point of care diagnostics market, by product.”
Based on product, the ASEAN point of care diagnostics market is segmented into infectious disease testing products, glucose monitoring products, cardiometabolic testing products, coagulation monitoring products, pregnancy & fertility testing products, urinalysis testing products, cancer marker testing products, cholesterol testing products, hematology testing products, fecal occult testing products, drugs-of-abuse testing products, and other POC products. Among them, the infectious disease testing products segment is expected to grow at the highest CAGR, primarily driven by the region’s continuous efforts towards enhancing disease surveillance and outbreak control. Recurrent outbreaks of infectious diseases, in addition to the requirement for rapid diagnosis in both urban & rural healthcare facilities, are fueling the demand for effective POC solutions. Additionally, the rapid development of advanced molecular platforms and immunoassays will facilitate the effective and smooth identification of infectious diseases, further expanding adoption among ASEAN countries.
“By technology, the Biochemistry segment accounted for the largest market share in the ASEAN point of care diagnostics market in 2024.”
The ASEAN point of care diagnostics market is segmented by technology into lateral flow assays (immunoassays), rapid tests (molecular diagnostics), and biochemistry. In 2024, the Biochemistry segment accounted for the largest share of the market owing to its extensive usability in a variety of routine & essential diagnostic tests such as blood glucose checks, electrolyte analysis, liver function tests, and kidney function tests. The high prevalence of chronic & lifestyle-associated diseases like diabetes, cardiovascular disease, and kidney disorders in the ASEAN countries has also substantially necessitated the need for point-of-care testing solutions based on biochemistry. Moreover, the ease of operation, cost-effectiveness, and shorter turnaround time of biochemistry analyzers make them appropriate for decentralized healthcare environments such as community clinics, primary health centers, and emergency departments. The growing demand for early disease detection & diagnosis has further supported the implementation of biochemistry-based POC solutions in the ASEAN market.
“Vietnam is the fastest-growing market for point of care diagnostics in the ASEAN region”
The ASEAN market for point of care diagnostics is categorized into Vietnam, Laos, Cambodia, Malaysia, Myanmar, Philippines, Singapore, Thailand, Indonesia, and Brunei. Vietnam is expected to grow at the highest CAGR during the forecast period. Vietnam’s strong focus on strengthening its primary healthcare network and expanding nationwide screening programs—especially after the COVID-19 pandemic—has significantly increased the adoption of point-of-care diagnostic solutions in public and private healthcare facilities. Additionally, the country is committed to improving the early detection and management of infectious diseases, bolstered by its robust disease surveillance and monitoring systems, which will support long-term market growth. As reflected in its Joint External Evaluation and Global Health Security Index scores, Vietnam’s impressive performance in global health security indicators highlights the healthcare system’s growing capacity to implement point-of-care diagnostics in the coming years.
The break-up of the profile of primary participants in the ASEAN point of care diagnostics market:
- By Company Type: Tier 1 – 40%, Tier 2 – 30%, and Tier 3 – 30%
- By Designation: C-level – 27%, D-level – 18%, and Others – 55%
The key players in this market are Abbott (US), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Sysmex Corporation (Japan), Danaher Corporation (US), BD (US), QuidelOrtho Corporation (US), Cardinal Health (US), AccuBioTech Co., Ltd. (China), EKF Diagnostics Holdings plc (UK), bioMérieux (France), Thermo Fisher Scientific Inc. (US), BIOSYNEX SA (France), PTS Diagnostics (US), LifeScan IP Holdings, LLC (US), SD Biosensor, INC. (South Korea), CTK Biotech, Inc. (US), Wondfo (China), Trinity Biotech (Ireland), SEKISUI Diagnostics (US), Werfen (Spain), ARKRAY, Inc. (US), Xiamen Boson Biotech Co., Ltd. (China), Credo Diagnostics Biomedical Pte. Ltd. (Singapore), Anbio Biotechnology Inc. (Germany), and SG Diagnostics (Singapore).
Research Coverage:
This research report categorizes the ASEAN point of care diagnostics market by product (infectious disease testing products, glucose monitoring products, cardiometabolic testing products, coagulation monitoring products, pregnancy & fertility testing products, urinalysis testing products, cancer marker testing products, cholesterol testing products, hematology testing products, fecal occult testing products, drugs-of-abuse testing products, and other POC products), by technology [lateral flow assays (immunoassays), rapid tests (molecular diagnostics), and biochemistry], by end user (clinical laboratories, hospitals and critical care centers, outpatient settings and ambulatory care centers, home care settings, and other end users) and by country (Vietnam, Laos, Cambodia, Malaysia, Myanmar, Philippines, Singapore, Thailand, Indonesia, and Brunei). The report provides comprehensive information on the key factors influencing the growth of the ASEAN point-of-care diagnostics market, including drivers, restraints, opportunities, and challenges. It includes a detailed analysis of the major industry players, offering insights into their business overviews, solutions, key strategies, acquisitions, and agreements. Additionally, the report discusses new product and service launches and recent developments in the point-of-care diagnostics market. A competitive analysis of emerging startups within the ASEAN point-of-care diagnostics ecosystem is also included.
Reasons to buy this report:
The report will help market leaders and new entrants with information on the closest approximations of the revenue numbers for the ASEAN point of care diagnostics market and its subsegments. It will also help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, opportunities, and challenges.
The report provides insights into the following points:
- Analysis of key drivers [Rising incidence of infectious diseases, increasing prevalence of chronic diseases, favorable government initiatives for POC testing, and the rising number of Public-Private Partnerships (PPPs)], opportunities (Gradual shift toward decentralized healthcare systems and availability of POC tests with multiplexing capabilities), restraints (Pricing pressure on manufacturers and stringent regulatory approval process for product commercialization), and challenges (Shortage of skilled healthcare providers and premium pricing of novel platforms) that influence the growth of the ASEAN point of care diagnostics market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the ASEAN point of care diagnostics market.
- Market Development: Comprehensive information about lucrative markets—the report analyses the ASEAN point of care diagnostics market across various countries.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the ASEAN point of care diagnostics market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like Abbott (US), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Sysmex Corporation (Japan), and Danaher Corporation (US).
Table of Contents
1 INTRODUCTION 27
1.1 STUDY OBJECTIVES 27
1.2 MARKET DEFINITION 27
1.3 STUDY SCOPE 28
1.3.1 MARKET SCOPE 28
1.3.2 INCLUSIONS & EXCLUSIONS 29
1.3.3 YEARS CONSIDERED 30
1.3.4 CURRENCY CONSIDERED 30
1.4 KEY STAKEHOLDERS 30
1.5 SUMMARY OF CHANGES 30
2 RESEARCH METHODOLOGY 32
2.1 RESEARCH DATA 32
2.1.1 SECONDARY DATA 32
2.1.1.1 Key secondary sources 33
2.1.1.2 Key data from secondary sources 33
2.1.1.3 Key objectives 34
2.1.2 PRIMARY DATA 34
2.1.2.1 Key primary sources 35
2.1.2.2 Key data from primary sources 35
2.1.2.3 Key industry insights 37
2.2 MARKET SIZE ESTIMATION 38
2.2.1 BOTTOM-UP APPROACH 39
2.2.1.1 Company revenue estimation approach 39
2.2.1.2 Presentations of companies & primary interviews 39
2.2.1.3 Growth forecast 40
2.2.1.4 CAGR projections 40
2.2.2 TOP-DOWN APPROACH 40
2.3 DATA TRIANGULATION 42
2.4 MARKET SHARE ANALYSIS 43
2.5 RESEARCH ASSUMPTIONS 43
2.5.1 GROWTH RATE ASSUMPTIONS 43
2.6 RESEARCH LIMITATIONS 44
2.7 RISK ASSESSMENT 44
3 EXECUTIVE SUMMARY 45
4 PREMIUM INSIGHTS 49
4.1 ASEAN POINT OF CARE DIAGNOSTICS MARKET OVERVIEW 49
4.2 ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2025 VS. 2030 50
4.3 ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2025 VS. 2030 50
4.4 ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2025 VS. 2030 51
4.5 ASEAN POINT OF CARE DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 51
5 MARKET OVERVIEW 52
5.1 INTRODUCTION 52
5.2 MARKET DYNAMICS 52
5.2.1 DRIVERS 53
5.2.1.1 Rising incidence of infectious diseases 53
5.2.1.2 Increasing prevalence of chronic diseases 55
5.2.1.3 Favorable government initiatives for POC testing 57
5.2.1.4 Rising number of public-private partnerships (PPPs) 58
5.2.2 RESTRAINTS 58
5.2.2.1 Pricing pressure on manufacturers 58
5.2.2.2 Stringent regulatory approval process for product commercialization 59
5.2.3 OPPORTUNITIES 59
5.2.3.1 Gradual shift toward decentralized healthcare systems 59
5.2.3.2 Availability of POC tests with multiplexing capabilities 60
5.2.4 CHALLENGES 60
5.2.4.1 Shortage of skilled healthcare providers 60
5.2.4.2 Premium pricing of novel platforms 61
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 61
5.4 PRICING ANALYSIS 62
5.4.1 INDICATIVE SELLING PRICE TREND OF POC TESTS, BY PRODUCT 62
5.4.2 INDICATIVE SELLING PRICE TREND OF GLUCOSE TEST STRIPS, BY KEY PLAYER 63
5.4.3 INDICATIVE SELLING PRICE TREND OF POC PREGNANCY TEST KITS,
BY COUNTRY 63
5.5 VALUE CHAIN ANALYSIS 64
5.6 SUPPLY CHAIN ANALYSIS 65
5.7 ECOSYSTEM ANALYSIS 66
5.8 INVESTMENT & FUNDING SCENARIO 68
5.9 TECHNOLOGY ANALYSIS 68
5.9.1 KEY TECHNOLOGIES 68
5.9.1.1 Lateral flow assays 68
5.9.2 COMPLEMENTARY TECHNOLOGIES 69
5.9.2.1 Molecular diagnostics 69
5.9.3 ADJACENT TECHNOLOGIES 70
5.9.3.1 Biochemical technologies 70
5.10 PATENT ANALYSIS 71
5.11 TRADE ANALYSIS 73
5.11.1 IMPORT DATA FOR HS CODE 3822 73
5.11.2 EXPORT DATA FOR HS CODE 3822 74
5.12 KEY CONFERENCES & EVENTS, 2025–2026 74
5.13 REGULATORY ANALYSIS 76
5.13.1 REGULATORY LANDSCAPE 76
5.13.1.1 Vietnam 76
5.13.1.2 Laos 76
5.13.1.3 Cambodia 77
5.13.1.4 Malaysia 77
5.13.1.5 Myanmar 78
5.13.1.6 Philippines 78
5.13.1.7 Singapore 79
5.13.1.8 Thailand 79
5.13.1.9 Indonesia 80
5.13.1.10 Brunei 80
5.13.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80
5.14 PORTER’S FIVE FORCES ANALYSIS 82
5.14.1 THREAT OF NEW ENTRANTS 83
5.14.2 THREAT OF SUBSTITUTES 83
5.14.3 BARGAINING POWER OF BUYERS 83
5.14.4 BARGAINING POWER OF SUPPLIERS 83
5.14.5 INTENSITY OF COMPETITIVE RIVALRY 84
5.15 KEY STAKEHOLDERS & BUYING CRITERIA 84
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS 84
5.15.2 KEY BUYING CRITERIA 85
5.16 IMPACT OF AI ON ASEAN POINT OF CARE DIAGNOSTICS MARKET 85
5.16.1 INTRODUCTION 85
5.16.2 MARKET POTENTIAL OF AI IN POC DIAGNOSTIC APPLICATIONS 86
5.16.3 AI USE CASES 86
5.16.4 KEY COMPANIES IMPLEMENTING AI 87
5.16.5 FUTURE OF AI IN ASEAN POINT OF CARE DIAGNOSTICS MARKET 88
6 ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT 89
6.1 INTRODUCTION 90
6.2 GLUCOSE MONITORING PRODUCTS 91
6.2.1 GLUCOMETERS 93
6.2.1.1 Accurate monitoring of blood sugar levels to drive market 93
6.2.2 GLUCOSE TEST STRIPS 95
6.2.2.1 Increasing uptake of single-use products to fuel market 95
6.2.3 LANCETS 97
6.2.3.1 Increasing preference for home-based care to support market growth 97
6.3 INFECTIOUS DISEASE TESTING PRODUCTS 98
6.3.1 RESPIRATORY INFECTION TESTING PRODUCTS 100
6.3.1.1 TB testing products 102
6.3.1.1.1 High prevalence of tuberculosis cases to fuel market 102
6.3.1.2 Influenza testing products 103
6.3.1.2.1 Rising need for targeted treatment therapies to boost demand 103
6.3.1.3 Other respiratory infection testing products 105
6.3.2 MOSQUITO-BORNE DISEASE TESTING PRODUCTS 107
6.3.2.1 Rising incidence of malaria & dengue to boost demand 107
6.3.3 STD TESTING PRODUCTS 109
6.3.3.1 Need to reduce disease transmission rates to facilitate growth 109
6.3.4 HIV TESTING PRODUCTS 111
6.3.4.1 Growing awareness of HIV POC testing to boost demand 111
6.3.5 HAI TESTING PRODUCTS 114
6.3.5.1 Growing incidence of HAIs in healthcare settings to drive market 114
6.3.6 HEPATITIS TESTING PRODUCTS 116
6.3.6.1 Hepatitis B testing products 117
6.3.6.1.1 Increasing prevalence of liver infections to fuel market 117
6.3.6.2 Hepatitis C testing products 119
6.3.6.2.1 Rising need to combat hepatitis among high-risk subgroups to support market growth 119
6.3.7 OTHER INFECTIOUS DISEASE TESTING PRODUCTS 121
6.4 COVID-19 TESTING PRODUCTS 123
6.4.1 GRADUAL SHIFT TOWARDS SYNDROMIC TESTING TO SUPPORT MARKET GROWTH 123
6.5 CARDIOMETABOLIC TESTING PRODUCTS 125
6.5.1 CARDIAC MARKER TESTING PRODUCTS 128
6.5.1.1 Early detection of myocardial infarctions and acute coronary syndromes to fuel market 128
6.5.2 HBA1C TESTING PRODUCTS 129
6.5.2.1 Provision of long-term measurement in blood glucose control to boost demand 129
6.5.3 BLOOD GAS & ELECTROLYTE TESTING PRODUCTS 130
6.5.3.1 Monitoring of key parameters for pH and oxygen saturation to drive market 130
6.6 COAGULATION MONITORING PRODUCTS 131
6.6.1 HIGH INCIDENCE OF BLEEDING DISORDERS TO FUEL UPTAKE 131
6.7 PREGNANCY & FERTILITY TESTING PRODUCTS 133
6.7.1 GROWING AWARENESS OF SUSTAINABLE FAMILY PLANNING TO PROPEL MARKET 133
6.8 HEMATOLOGY TESTING PRODUCTS 136
6.8.1 RISING DEMAND FOR BLOOD TRANSFUSION PROCEDURES TO DRIVE MARKET 136
6.9 CANCER MARKER TESTING PRODUCTS 138
6.9.1 INCREASING PREFERENCE FOR PERSONALIZED ONCOLOGY THERAPEUTICS TO PROPEL MARKET 138
6.10 FECAL OCCULT TESTING PRODUCTS 141
6.10.1 FAVORABLE INITIATIVES FOR COLORECTAL CANCER SCREENING TO BOOST MARKET 141
6.11 CHOLESTEROL TESTING PRODUCTS 143
6.11.1 RISING OBESITY RATE CAUSED BY SEDENTARY LIFESTYLES TO DRIVE MARKET 143
6.12 URINALYSIS TESTING PRODUCTS 145
6.12.1 RISING PREVALENCE OF UTIS AND KIDNEY DISEASES TO DRIVE MARKET 145
6.13 DRUGS-OF-ABUSE TESTING PRODUCTS 147
6.13.1 HIGH CONSUMPTION OF ILLICIT DRUGS TO FUEL MARKET 147
6.14 OTHER POC PRODUCTS 149
7 ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY 151
7.1 INTRODUCTION 152
7.2 BIOCHEMISTRY 152
7.2.1 PROVISION OF RAPID ONSITE RESULTS FOR CHRONIC CONDITIONS TO DRIVE MARKET 152
7.3 LATERAL FLOW ASSAYS (IMMUNOASSAYS) 154
7.3.1 INTEGRATION OF ELISA INTO DISPOSABLE TESTING STRIPS FOR COMPLEX LABORATORY ANALYSIS TO FUEL MARKET 154
7.4 RAPID TESTS (MOLECULAR DIAGNOSTICS) 157
7.4.1 ANALYSIS OF BIOLOGICAL MARKERS FOR RAPID DISEASE DETECTION TO PROPEL MARKET 157
8 ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER 159
8.1 INTRODUCTION 160
8.2 HOME CARE SETTINGS 160
8.2.1 GROWING CONSUMER PREFERENCE FOR CONVENIENCE AND AFFORDABILITY TO PROPEL MARKET 160
8.3 CLINICAL LABORATORIES 162
8.3.1 MANAGEMENT OF HIGH PATIENT VOLUMES WITH AUTOMATED TESTING SOLUTIONS TO FUEL MARKET 162
8.4 HOSPITALS AND CRITICAL CARE CENTERS 163
8.4.1 RISING REQUIREMENT FOR RAPID POC TESTING IN EMERGENCY USE TO SUPPORT MARKET GROWTH 163
8.5 OUTPATIENT SETTINGS AND AMBULATORY CARE CENTERS 165
8.5.1 COST-EFFECTIVENESS OVER HOSPITALS TO BOOST MARKET GROWTH 165
8.6 OTHER END USERS 166
9 ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY 168
9.1 INTRODUCTION 169
9.1.1 MACROECONOMIC OUTLOOK FOR ASEAN COUNTRIES 171
9.2 INDONESIA 172
9.2.1 RISING PUBLIC AWARENESS ABOUT PREVENTIVE HEALTHCARE TO DRIVE MARKET 172
9.2.2 MACROECONOMIC OUTLOOK FOR INDONESIA 173
9.3 THAILAND 178
9.3.1 EXPANDING GERIATRIC POPULATION AND SUBSEQUENT RISE IN CHRONIC DISEASES TO FUEL MARKET 178
9.3.2 MACROECONOMIC OUTLOOK FOR THAILAND 179
9.4 MALAYSIA 184
9.4.1 HIGH INCIDENCE OF DIABETES TO BOOST DEMAND 184
9.4.2 MACROECONOMIC OUTLOOK FOR MALAYSIA 185
9.5 PHILIPPINES 190
9.5.1 IMPROVED HEALTHCARE ACCESS AND INSURANCE COVERAGE TO FUEL ADOPTION 190
9.5.2 MACROECONOMIC OUTLOOK FOR PHILIPPINES 191
9.6 VIETNAM 196
9.6.1 IMPROVING HEALTHCARE INFRASTRUCTURE AND FAVORABLE GOVERNMENT INITIATIVES TO PROPEL MARKET 196
9.6.2 MACROECONOMIC OUTLOOK FOR VIETNAM 197
9.7 SINGAPORE 202
9.7.1 INCREASING DEMAND FOR SPECIALIZED MEDICAL SERVICES TO BOOST MARKET 202
9.7.2 MACROECONOMIC OUTLOOK FOR SINGAPORE 203
9.8 MYANMAR 208
9.8.1 RISING NEED FOR AFFORDABLE DIAGNOSTIC SOLUTIONS TO DRIVE MARKET 208
9.8.2 MACROECONOMIC OUTLOOK FOR MYANMAR 209
9.9 CAMBODIA 214
9.9.1 RISING PREVALENCE OF NCDS TO SUPPORT MARKET GROWTH 214
9.9.2 MACROECONOMIC OUTLOOK FOR CAMBODIA 215
9.10 LAOS 220
9.10.1 NEED FOR DECENTRALIZED DIAGNOSTIC SOLUTIONS TO FUEL DEMAND 220
9.10.2 MACROECONOMIC OUTLOOK FOR LAOS 221
9.11 BRUNEI 226
9.11.1 GROWING NEED FOR COST-EFFECTIVE POC SOLUTIONS TO FUEL MARKET 226
9.11.2 MACROECONOMIC OUTLOOK FOR BRUNEI 227
10 COMPETITIVE LANDSCAPE 233
10.1 INTRODUCTION 233
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 233
10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN ASEAN POINT OF CARE DIAGNOSTICS MARKET 234
10.3 REVENUE ANALYSIS, 2022–2024 236
10.4 MARKET SHARE ANALYSIS, 2024 237
10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 238
10.5.1 STARS 239
10.5.2 EMERGING LEADERS 239
10.5.3 PERVASIVE PLAYERS 239
10.5.4 PARTICIPANTS 239
10.5.5 COMPANY FOOTPRINT, KEY PLAYERS, 2024 241
10.5.5.1 Company footprint 241
10.5.5.2 Country footprint 242
10.5.5.3 Product footprint 243
10.5.5.4 Technology footprint 245
10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 246
10.6.1 PROGRESSIVE COMPANIES 246
10.6.2 RESPONSIVE COMPANIES 246
10.6.3 DYNAMIC COMPANIES 246
10.6.4 STARTING BLOCKS 246
10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 248
10.6.5.1 Detailed list of key startups/SMEs 248
10.6.5.2 Competitive benchmarking of key startups/SMEs, by technology 248
10.6.5.3 Competitive benchmarking of key startups/SMEs, by country 249
10.7 COMPANY VALUATION & FINANCIAL METRICS 249
10.7.1 FINANCIAL METRICS 249
10.7.2 COMPANY VALUATION 250
10.8 BRAND/PRODUCT COMPARISON 250
10.9 COMPETITIVE SCENARIO 251
10.9.1 PRODUCT LAUNCHES & APPROVALS 251
10.9.2 DEALS 252
10.9.3 EXPANSIONS 253
11 COMPANY PROFILES 254
11.1 KEY PLAYERS 254
11.1.1 ABBOTT 254
11.1.1.1 Business overview 254
11.1.1.2 Products offered 255
11.1.1.3 Recent developments 258
11.1.1.3.1 Product approvals 258
11.1.1.3.2 Deals 258
11.1.1.4 MnM view 259
11.1.1.4.1 Key strengths 259
11.1.1.4.2 Strategic choices 259
11.1.1.4.3 Weaknesses & competitive threats 259
11.1.2 F. HOFFMANN-LA ROCHE LTD. 260
11.1.2.1 Business overview 260
11.1.2.2 Products offered 261
11.1.2.3 Recent developments 263
11.1.2.3.1 Product launches & approvals 263
11.1.2.3.2 Deals 264
11.1.2.4 MnM view 265
11.1.2.4.1 Key strengths 265
11.1.2.4.2 Strategic choices 265
11.1.2.4.3 Weaknesses & competitive threats 265
11.1.3 SIEMENS HEALTHINEERS AG 266
11.1.3.1 Business overview 266
11.1.3.2 Products offered 267
11.1.3.3 Recent developments 269
11.1.3.3.1 Product approvals 269
11.1.3.3.2 Deals 269
11.1.3.3.3 Expansions 271
11.1.3.4 MnM view 271
11.1.3.4.1 Key strengths 271
11.1.3.4.2 Strategic choices 271
11.1.3.4.3 Weaknesses & competitive threats 271
11.1.4 SYSMEX CORPORATION 272
11.1.4.1 Business overview 272
11.1.4.2 Products offered 273
11.1.4.3 Recent developments 274
11.1.4.3.1 Expansions 274
11.1.4.4 MnM view 274
11.1.4.4.1 Key strengths 274
11.1.4.4.2 Strategic choices 274
11.1.4.4.3 Weaknesses & competitive threats 275
11.1.5 DANAHER CORPORATION 276
11.1.5.1 Business overview 276
11.1.5.2 Products offered 277
11.1.5.3 MnM view 278
11.1.5.3.1 Key strengths 278
11.1.5.3.2 Strategic choices 279
11.1.5.3.3 Weaknesses and competitive threats 279
11.1.6 BD 280
11.1.6.1 Business overview 280
11.1.6.2 Products offered 281
11.1.6.3 Recent developments 282
11.1.6.3.1 Deals 282
11.1.6.3.2 Expansions 282
11.1.7 QUIDELORTHO CORPORATION 283
11.1.7.1 Business overview 283
11.1.7.2 Recent developments 287
11.1.7.2.1 Product approvals 287
11.1.7.2.2 Deals 288
11.1.7.2.3 Expansions 290
11.1.8 CARDINAL HEALTH 291
11.1.8.1 Business overview 291
11.1.8.2 Products offered 292
11.1.8.3 Recent developments 293
11.1.8.3.1 Deals 293
11.1.8.3.2 Expansions 294
11.1.9 BIOMÉRIEUX 295
11.1.9.1 Business overview 295
11.1.9.2 Products offered 296
11.1.9.3 Recent developments 297
11.1.9.3.1 Product approvals 297
11.1.9.3.2 Deals 298
11.1.10 EKF DIAGNOSTICS HOLDINGS PLC 299
11.1.10.1 Business overview 299
11.1.10.2 Products offered 300
11.1.10.3 Recent developments 301
11.1.10.3.1 Product launches 301
11.1.10.3.2 Deals 301
11.1.10.3.3 Expansions 301
11.1.11 THERMO FISHER SCIENTIFIC INC. 302
11.1.11.1 Business overview 302
11.1.11.2 Products offered 303
11.1.11.3 Recent developments 304
11.1.11.3.1 Product launches 304
11.1.11.3.2 Deals 304
11.1.12 ACCUBIOTECH, CO., LTD. 305
11.1.12.1 Business overview 305
11.1.12.2 Products offered 305
11.1.12.3 Recent developments 307
11.1.12.3.1 Product approvals 307
11.2 OTHER PLAYERS 308
11.2.1 BIOSYNEX SA 308
11.2.2 SD BIOSENSOR, INC. 309
11.2.3 SEKISUI DIAGNOSTICS 311
11.2.4 WERFEN 312
11.2.5 TRINITY BIOTECH 313
11.2.6 PTS DIAGNOSTICS 314
11.2.7 LIFESCAN IP HOLDINGS, LLC 315
11.2.8 CTK BIOTECH, INC. 316
11.2.9 WONDFO 318
11.2.10 ARKRAY, INC. 319
11.2.11 XIAMEN BOSON BIOTECH CO., LTD. 320
11.2.12 CREDO DIAGNOSTICS BIOMEDICAL PTE. LTD. 322
11.2.13 ANBIO BIOTECHNOLOGY INC. 323
11.2.14 SG DIAGNOSTICS 325
12 APPENDIX 326
12.1 DISCUSSION GUIDE 326
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 330
12.3 AVAILABLE CUSTOMIZATIONS 332
12.4 RELATED REPORTS 332
12.5 AUTHOR DETAILS 333
LIST OF TABLES
TABLE 1 ASEAN POINT OF CARE DIAGNOSTICS MARKET: KEY DATA FROM PRIMARY SOURCES 35
TABLE 2 ASEAN POINT OF CARE DIAGNOSTICS MARKET: RISK ASSESSMENT ANALYSIS 44
TABLE 3 HEPATITIS DISEASE BURDEN AND DEATHS CAUSED BY HEPATITIS, BY COUNTRY (2022) 54
TABLE 4 DIABETES ESTIMATES (AGES 20–79) AND DIABETES-RELATED DEATHS,
BY COUNTRY, 2021 56
TABLE 5 PROJECTED INCREASE IN CANCER PATIENTS, BY COUNTRY,
2022 VS. 2035 VS. 2045 56
TABLE 6 INDICATIVE SELLING PRICE TREND OF POC TESTS, BY PRODUCT, 2023–2025 62
TABLE 7 INDICATIVE SELLING PRICE TREND OF GLUCOSE TEST STRIPS, BY KEY PLAYER, 2023−2025 63
TABLE 8 INDICATIVE SELLING PRICE TREND OF POC PREGNANCY TEST KITS, BY COUNTRY, 2023–2025 63
TABLE 9 ASEAN POINT OF CARE DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM 67
TABLE 10 ASEAN POINT OF CARE DIAGNOSTICS MARKET: INNOVATIONS & PATENT REGISTRATIONS, 2022–2024 72
TABLE 11 IMPORT DATA FOR DIAGNOSTIC & LABORATORY REAGENTS (HS CODE 3822),
BY COUNTRY, 2020–2024 (USD THOUSAND) 73
TABLE 12 EXPORT DATA FOR DIAGNOSTIC & LABORATORY REAGENTS (HS CODE 3822),
BY COUNTRY, 2020–2024 (USD THOUSAND) 74
TABLE 13 ASEAN POC DIAGNOSTICS MARKET: KEY CONFERENCES & EVENTS, 2025–2026 74
TABLE 14 MALAYSIA: CLASSIFICATION OF IVD MEDICAL DEVICES 77
TABLE 15 MYANMAR: CLASSIFICATION OF IVD MEDICAL DEVICES 78
TABLE 16 ASEAN COUNTRIES: KEY REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 80
TABLE 17 ASEAN POINT OF CARE DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 83
TABLE 18 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TECHNOLOGY (%) 84
TABLE 19 KEY BUYING CRITERIA, BY TECHNOLOGY 85
TABLE 20 ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT,
2022–2030 (USD MILLION) 90
TABLE 21 DIABETES PREVALENCE (20–79 YRS), DIABETES-RELATED DEATHS, AND PROPORTION OF UNDIAGNOSED DIABETES, BY COUNTRY, 2021 91
TABLE 22 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION) 92
TABLE 23 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION) 93
TABLE 24 GLUCOMETERS: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY 94
TABLE 25 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOMETERS, BY COUNTRY, 2022–2030 (USD MILLION) 95
TABLE 26 GLUCOSE TEST STRIPS: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY 96
TABLE 27 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE TEST STRIPS,
BY COUNTRY, 2022–2030 (USD MILLION) 96
TABLE 28 LANCETS & LANCING DEVICES: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY 97
TABLE 29 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR LANCETS, BY COUNTRY,
2022–2030 (USD MILLION) 98
TABLE 30 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY DISEASE TYPE, 2022–2030 (USD MILLION) 99
TABLE 31 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION) 100
TABLE 32 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION) 101
TABLE 33 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION) 101
TABLE 34 TB TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY 102
TABLE 35 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR TB TESTING PRODUCTS,
BY COUNTRY, 2022–2030 (USD MILLION) 103
TABLE 36 INFLUENZA TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY 104
TABLE 37 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION) 105
TABLE 38 OTHER RESPIRATORY INFECTION TESTING: CURRENTLY AVAILABLE PRODUCTS,
BY COMPANY 106
TABLE 39 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION) 107
TABLE 40 MOSQUITO-BORNE DISEASE TESTING: CURRENTLY AVAILABLE PRODUCTS,
BY COMPANY 108
TABLE 41 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION) 109
TABLE 42 STD TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY 110
TABLE 43 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR STD TESTING PRODUCTS,
BY COUNTRY, 2022–2030 (USD MILLION) 111
TABLE 44 HIV TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY 112
TABLE 45 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS,
BY COUNTRY, 2022–2030 (USD MILLION) 113
TABLE 46 HAI TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY 115
TABLE 47 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HAI TESTING PRODUCTS,
BY COUNTRY, 2022–2030 (USD MILLION) 115
TABLE 48 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION) 116
TABLE 49 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION) 117
TABLE 50 HEPATITIS B TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY 118
TABLE 51 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS B TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION) 119
TABLE 52 HEPATITIS C TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY 120
TABLE 53 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION) 121
TABLE 54 OTHER INFECTIOUS DISEASE TESTING: CURRENTLY AVAILABLE PRODUCTS,
BY COMPANY 122
TABLE 55 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION) 123
TABLE 56 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR COVID-19 TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION) 124
TABLE 57 CARDIOMETABOLIC TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY 125
TABLE 58 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION) 127
TABLE 59 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION) 127
TABLE 60 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION) 129
TABLE 61 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION) 130
TABLE 62 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD GAS & ELECTROLYTE TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION) 131
TABLE 63 COAGULATION MONITORING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY 132
TABLE 64 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION) 133
TABLE 65 PREGNANCY & FERTILITY TESTING: CURRENTLY AVAILABLE PRODUCTS,
BY COMPANY 134
TABLE 66 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION) 135
TABLE 67 ASEAN POINT OF CARE DIAGNOSTICS MARKET: TOTAL NUMBER OF PREGNANCIES, BY COUNTRY, 2022−2030 (IN MILLION) 136
TABLE 68 HEMATOLOGY TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY 137
TABLE 69 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION) 138
TABLE 70 NUMBER OF CASES FOR TOP FIVE CANCER TYPES, 2022 139
TABLE 71 CANCER MARKER TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY 140
TABLE 72 ASEAN POINT OF CARE DIAGNOSTICS MARKET OF CANCER MARKER TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION) 140
TABLE 73 ESTIMATED NUMBER OF NEW CASES OF COLORECTAL CANCER,
2022 VS. 2035 VS. 2045 142
TABLE 74 FECAL OCCULT BLOOD TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY 142
TABLE 75 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR FECAL OCCULT BLOOD TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION) 143
TABLE 76 CHOLESTEROL TESTING PRODUCTS: CURRENTLY AVAILABLE PRODUCTS,
BY COMPANY 144
TABLE 77 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION) 145
TABLE 78 URINALYSIS TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY 146
TABLE 79 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION) 147
TABLE 80 DRUGS-OF-ABUSE TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY 148
TABLE 81 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION) 149
TABLE 82 OTHER POC PRODUCTS: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY 150
TABLE 83 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR OTHER POC PRODUCTS,
BY COUNTRY, 2022–2030 (USD MILLION) 150
TABLE 84 ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY,
2022–2030 (USD MILLION) 152
TABLE 85 BIOCHEMISTRY: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY 153
TABLE 86 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY COUNTRY, 2022–2030 (USD MILLION) 154
TABLE 87 LATERAL FLOW ASSAYS: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY 155
TABLE 88 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR LATERAL FLOW ASSAYS (IMMUNOASSAYS), BY COUNTRY, 2022–2030 (USD MILLION) 156
TABLE 89 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR RAPID TESTS
(MOLECULAR DIAGNOSTICS), BY COUNTRY, 2022–2030 (USD MILLION) 158
TABLE 90 ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER,
2022–2030 (USD MILLION) 160
TABLE 91 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HOME CARE SETTINGS,
BY COUNTRY, 2022–2030 (USD MILLION) 161
TABLE 92 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES,
BY COUNTRY, 2022–2030 (USD MILLION) 163
TABLE 93 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HOSPITALS AND CRITICAL CARE CENTERS, BY COUNTRY, 2022–2030 (USD MILLION) 165
TABLE 94 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR OUTPATIENT SETTINGS AND AMBULATORY CARE CENTERS, BY COUNTRY, 2022–2030 (USD MILLION) 166
TABLE 95 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR OTHER END USERS,
BY COUNTRY, 2022–2030 (USD MILLION) 167
TABLE 96 ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 171
TABLE 97 INDONESIA: MACROECONOMIC INDICATORS FOR ASEAN POINT OF CARE DIAGNOSTICS MARKET 173
TABLE 98 INDONESIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT,
2022–2030 (USD MILLION) 174
TABLE 99 INDONESIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY DISEASE TYPE, 2022–2030 (USD MILLION) 175
TABLE 100 INDONESIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION) 175
TABLE 101 INDONESIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION) 176
TABLE 102 INDONESIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION) 176
TABLE 103 INDONESIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE,
2022–2030 (USD MILLION) 176
TABLE 104 INDONESIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 177
TABLE 105 INDONESIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TECHNOLOGY, 2022–2030 (USD MILLION) 177
TABLE 106 INDONESIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER,
2022–2030 (USD MILLION) 178
TABLE 107 THAILAND: MACROECONOMIC INDICATORS FOR ASEAN POINT OF CARE DIAGNOSTICS MARKET 179
TABLE 108 THAILAND: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT,
2022–2030 (USD MILLION) 180
TABLE 109 THAILAND: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY DISEASE TYPE, 2022–2030 (USD MILLION) 181
TABLE 110 THAILAND: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION) 181
TABLE 111 THAILAND: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION) 182
TABLE 112 THAILAND: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION) 182
TABLE 113 THAILAND: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION) 182
TABLE 114 THAILAND: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 183
TABLE 115 THAILAND: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TECHNOLOGY, 2022–2030 (USD MILLION) 183
TABLE 116 THAILAND: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER,
2022–2030 (USD MILLION) 184
TABLE 117 MALAYSIA: MACROECONOMIC INDICATORS FOR ASEAN POINT OF CARE DIAGNOSTICS MARKET 186
TABLE 118 MALAYSIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT,
2022–2030 (USD MILLION) 186
TABLE 119 MALAYSIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY DISEASE TYPE, 2022–2030 (USD MILLION) 187
TABLE 120 MALAYSIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION) 187
TABLE 121 MALAYSIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION) 188
TABLE 122 MALAYSIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION) 188
TABLE 123 MALAYSIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION) 188
TABLE 124 MALAYSIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 189
TABLE 125 MALAYSIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TECHNOLOGY, 2022–2030 (USD MILLION) 189
TABLE 126 MALAYSIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER,
2022–2030 (USD MILLION) 190
TABLE 127 PHILIPPINES: MACROECONOMIC INDICATORS FOR ASEAN POINT OF CARE DIAGNOSTICS MARKET 191
TABLE 128 PHILIPPINES: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT,
2022–2030 (USD MILLION) 192
TABLE 129 PHILIPPINES: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY DISEASE TYPE, 2022–2030 (USD MILLION) 193
TABLE 130 PHILIPPINES: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION) 193
TABLE 131 PHILIPPINES: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION) 194
TABLE 132 PHILIPPINES: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION) 194
TABLE 133 PHILIPPINES: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE,
2022–2030 (USD MILLION) 194
TABLE 134 PHILIPPINES: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 195
TABLE 135 PHILIPPINES: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TECHNOLOGY, 2022–2030 (USD MILLION) 195
TABLE 136 PHILIPPINES: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 196
TABLE 137 VIETNAM: MACROECONOMIC INDICATORS FOR ASEAN POINT OF CARE DIAGNOSTICS MARKET 198
TABLE 138 VIETNAM: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT,
2022–2030 (USD MILLION) 198
TABLE 139 VIETNAM: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY DISEASE TYPE, 2022–2030 (USD MILLION) 199
TABLE 140 VIETNAM: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION) 199
TABLE 141 VIETNAM: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION) 200
TABLE 142 VIETNAM: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION) 200
TABLE 143 VIETNAM: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION) 200
TABLE 144 VIETNAM: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY,
2022–2030 (USD MILLION) 201
TABLE 145 VIETNAM: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TECHNOLOGY, 2022–2030 (USD MILLION) 201
TABLE 146 VIETNAM: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER,
2022–2030 (USD MILLION) 202
TABLE 147 SINGAPORE: MACROECONOMIC INDICATORS FOR ASEAN POINT OF CARE DIAGNOSTICS MARKET 204
TABLE 148 SINGAPORE: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT,
2022–2030 (USD MILLION) 204
TABLE 149 SINGAPORE: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY DISEASE TYPE, 2022–2030 (USD MILLION) 205
TABLE 150 SINGAPORE: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION) 205
TABLE 151 SINGAPORE: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION) 206
TABLE 152 SINGAPORE: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION) 206
TABLE 153 SINGAPORE: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE,
2022–2030 (USD MILLION) 206
TABLE 154 SINGAPORE: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 207
TABLE 155 SINGAPORE: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TECHNOLOGY, 2022–2030 (USD MILLION) 207
TABLE 156 SINGAPORE: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER,
2022–2030 (USD MILLION) 208
TABLE 157 MYANMAR: MACROECONOMIC INDICATORS FOR ASEAN POINT OF CARE DIAGNOSTICS MARKET 210
TABLE 158 MYANMAR: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT,
2022–2030 (USD MILLION) 210
TABLE 159 MYANMAR: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY DISEASE TYPE, 2022–2030 (USD MILLION) 211
TABLE 160 MYANMAR: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION) 211
TABLE 161 MYANMAR: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION) 212
TABLE 162 MYANMAR: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION) 212
TABLE 163 MYANMAR: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION) 212
TABLE 164 MYANMAR: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 213
TABLE 165 MYANMAR: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TECHNOLOGY, 2022–2030 (USD MILLION) 213
TABLE 166 MYANMAR: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER,
2022–2030 (USD MILLION) 214
TABLE 167 CAMBODIA: MACROECONOMIC INDICATORS FOR ASEAN POINT OF CARE DIAGNOSTICS MARKET 215
TABLE 168 CAMBODIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT,
2022–2030 (USD MILLION) 216
TABLE 169 CAMBODIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY DISEASE TYPE, 2022–2030 (USD MILLION) 217
TABLE 170 CAMBODIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION) 217
TABLE 171 CAMBODIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION) 218
TABLE 172 CAMBODIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION) 218
TABLE 173 CAMBODIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE,
2022–2030 (USD MILLION) 218
TABLE 174 CAMBODIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 219
TABLE 175 CAMBODIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TECHNOLOGY, 2022–2030 (USD MILLION) 219
TABLE 176 CAMBODIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER,
2022–2030 (USD MILLION) 220
TABLE 177 LAOS: MACROECONOMIC INDICATORS FOR ASEAN POINT OF CARE DIAGNOSTICS MARKET 221
TABLE 178 LAOS: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT,
2022–2030 (USD MILLION) 222
TABLE 179 LAOS: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY DISEASE TYPE, 2022–2030 (USD MILLION) 223
TABLE 180 LAOS: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION) 223
TABLE 181 LAOS: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION) 224
TABLE 182 LAOS: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION) 224
TABLE 183 LAOS: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION) 224
TABLE 184 LAOS: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY,
2022–2030 (USD MILLION) 225
TABLE 185 LAOS: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TECHNOLOGY, 2022–2030 (USD MILLION) 225
TABLE 186 LAOS: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER,
2022–2030 (USD MILLION) 226
TABLE 187 BRUNEI: MACROECONOMIC INDICATORS FOR ASEAN POINT OF CARE DIAGNOSTICS MARKET 227
TABLE 188 BRUNEI: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT,
2022–2030 (USD MILLION) 228
TABLE 189 BRUNEI: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY DISEASE TYPE, 2022–2030 (USD MILLION) 229
TABLE 190 BRUNEI: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION) 229
TABLE 191 BRUNEI: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION) 230
TABLE 192 BRUNEI: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION) 230
TABLE 193 BRUNEI: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION) 230
TABLE 194 BRUNEI: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY,
2022–2030 (USD MILLION) 231
TABLE 195 BRUNEI: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TECHNOLOGY, 2022–2030 (USD MILLION) 231
TABLE 196 BRUNEI: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER,
2022–2030 (USD MILLION) 232
TABLE 197 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN ASEAN POINT OF CARE DIAGNOSTICS MARKET, JANUARY 2021−MARCH 2025 234
TABLE 198 ASEAN POINT OF CARE DIAGNOSTICS MARKET: DEGREE OF COMPETITION 237
TABLE 199 ASEAN POINT OF CARE DIAGNOSTICS MARKET: COUNTRY FOOTPRINT 242
TABLE 200 ASEAN POINT OF CARE DIAGNOSTICS MARKET: PRODUCT FOOTPRINT 243
TABLE 201 ASEAN POINT OF CARE DIAGNOSTICS MARKET: TECHNOLOGY FOOTPRINT 245
TABLE 202 ASEAN POINT OF CARE DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 248
TABLE 203 ASEAN POINT OF CARE DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES, BY TECHNOLOGY 248
TABLE 204 ASEAN POINT OF CARE DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES, BY COUNTRY 249
TABLE 205 ASEAN POINT OF CARE DIAGNOSTICS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MARCH 2025 251
TABLE 206 ASEAN POINT OF CARE DIAGNOSTICS MARKET: DEALS,
JANUARY 2021–MARCH 2025 252
TABLE 207 ASEAN POINT OF CARE DIAGNOSTICS MARKET: EXPANSIONS,
JANUARY 2021–MARCH 2025 253
TABLE 208 ABBOTT: COMPANY OVERVIEW 254
TABLE 209 ABBOTT: PRODUCTS OFFERED 255
TABLE 210 ABBOTT: PRODUCT APPROVALS, JANUARY 2021–MARCH 2025 258
TABLE 211 ABBOTT: DEALS, JANUARY 2021– MARCH 2025 258
TABLE 212 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 260
TABLE 213 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED 261
TABLE 214 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2021–MARCH 2025 263
TABLE 215 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021– MARCH 2025 264
TABLE 216 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 266
TABLE 217 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED 267
TABLE 218 SIEMENS HEALTHINEERS AG: PRODUCT APPROVALS,
JANUARY 2021–MARCH 2025 269
TABLE 219 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2021– MARCH 2025 269
TABLE 220 SIEMENS HEALTHINEERS AG: EXPANSIONS, JANUARY 2021– MARCH 2025 271
TABLE 221 SYSMEX CORPORATION: COMPANY OVERVIEW 272
TABLE 222 SYSMEX CORPORATION: PRODUCTS OFFERED 273
TABLE 223 SYSMEX CORPORATION: EXPANSIONS, JANUARY 2021−MARCH 2025 274
TABLE 224 DANAHER CORPORATION: COMPANY OVERVIEW 276
TABLE 225 DANAHER CORPORATION: PRODUCTS OFFERED 277
TABLE 226 BD: COMPANY OVERVIEW 280
TABLE 227 BD: PRODUCTS OFFERED 281
TABLE 228 BD: DEALS, JANUARY 2021–MARCH 2025 282
TABLE 229 BD: EXPANSIONS, JANUARY 2021–MARCH 2025 282
TABLE 230 QUIDELORTHO CORPORATION: COMPANY OVERVIEW 283
TABLE 231 QUIDELORTHO CORPORATION: PRODUCTS OFFERED 284
TABLE 232 QUIDELORTHO CORPORATION: PRODUCT APPROVALS,
JANUARY 2021–MARCH 2025 287
TABLE 233 QUIDELORTHO CORPORATION: DEALS, JANUARY 2021–MARCH 2025 288
TABLE 234 QUIDELORTHO CORPORATION: EXPANSIONS, JANUARY 2021–MARCH 2025 290
TABLE 235 CARDINAL HEALTH: COMPANY OVERVIEW 291
TABLE 236 CARDINAL HEALTH: PRODUCTS OFFERED 292
TABLE 237 CARDINAL HEALTH: DEALS, JANUARY 2021–MARCH 2025 293
TABLE 238 CARDINAL HEALTH: EXPANSIONS, JANUARY 2021–MARCH 2025 294
TABLE 239 BIOMÉRIEUX: COMPANY OVERVIEW 295
TABLE 240 BIOMÉRIEUX: PRODUCTS OFFERED 296
TABLE 241 BIOMÉRIEUX: PRODUCT APPROVALS, JANUARY 2021–MARCH 2025 297
TABLE 242 BIOMÉRIEUX: DEALS, JANUARY 2021–MARCH 2025 298
TABLE 243 EKF DIAGNOSTICS HOLDINGS PLC: COMPANY OVERVIEW 299
TABLE 244 EKF DIAGNOSTICS HOLDINGS PLC: PRODUCTS OFFERED 300
TABLE 245 EKF DIAGNOSTICS HOLDINGS PLC: PRODUCT LAUNCHES,
JANUARY 2021–MARCH 2025 301
TABLE 246 EKF DIAGNOSTICS HOLDINGS PLC: DEALS, JANUARY 2021–MARCH 2025 301
TABLE 247 EKF DIAGNOSTICS HOLDINGS PLC: EXPANSIONS, JANUARY 2021–MARCH 2025 301
TABLE 248 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 302
TABLE 249 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 303
TABLE 250 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES,
JANUARY 2021–MARCH 2025 304
TABLE 251 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021–MARCH 2025 304
TABLE 252 ACCUBIOTECH CO., LTD.: COMPANY OVERVIEW 305
TABLE 253 ACCUBIOTECH CO., LTD.: PRODUCTS OFFERED 305
TABLE 254 ACCUBIOTECH CO., LTD.: PRODUCT APPROVALS, JANUARY 2021–MARCH 2025 307
TABLE 255 BIOSYNEX SA: COMPANY OVERVIEW 308
TABLE 256 SD BIOSENSOR, INC.: COMPANY OVERVIEW 309
TABLE 257 SEKISUI DIAGNOSTICS: COMPANY OVERVIEW 311
TABLE 258 WERFEN: COMPANY OVERVIEW 312
TABLE 259 TRINITY BIOTECH: COMPANY OVERVIEW 313
TABLE 260 PTS DIAGNOSTICS: COMPANY OVERVIEW 314
TABLE 261 LIFESCAN IP HOLDINGS, LLC: COMPANY OVERVIEW 315
TABLE 262 CTK BIOTECH, INC.: COMPANY OVERVIEW 316
TABLE 263 WONDFO: COMPANY OVERVIEW 318
TABLE 264 ARKRAY, INC.: COMPANY OVERVIEW 319
TABLE 265 XIAMEN BOSON BIOTECH CO., LTD.: COMPANY OVERVIEW 320
TABLE 266 CREDO DIAGNOSTICS BIOMEDICAL PTE. LTD.: COMPANY OVERVIEW 322
TABLE 267 ANBIO BIOTECHNOLOGY INC.: COMPANY OVERVIEW 323
TABLE 268 SG DIAGNOSTICS: COMPANY OVERVIEW 325
LIST OF FIGURES
FIGURE 1 MARKETS COVERED & REGIONS CONSIDERED 28
FIGURE 2 ASEAN POINT OF CARE DIAGNOSTICS MARKET: RESEARCH DESIGN 32
FIGURE 3 ASEAN POINT OF CARE DIAGNOSTICS MARKET: KEY INDUSTRY INSIGHTS 37
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS 37
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE AND DESIGNATION 38
FIGURE 6 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 39
FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 40
FIGURE 8 ASEAN POINT OF CARE DIAGNOSTICS MARKET: TOP-DOWN APPROACH 41
FIGURE 9 ASEAN POINT OF CARE DIAGNOSTICS MARKET: DATA TRIANGULATION METHODOLOGY 42
FIGURE 10 ASEAN POINT OF CARE DIAGNOSTICS MARKET: RESEARCH ASSUMPTIONS 43
FIGURE 11 ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT,
2025 VS. 2030 (USD MILLION) 45
FIGURE 12 ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY,
2025 VS. 2030 (USD MILLION) 46
FIGURE 13 ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER,
2025 VS. 2030 (USD MILLION) 47
FIGURE 14 ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY,
2025 VS. 2030 (USD MILLION) 48
FIGURE 15 RISING PREVALENCE OF INFECTIOUS DISEASES TO PROPEL MARKET 49
FIGURE 16 GLUCOSE MONITORING PRODUCTS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 50
FIGURE 17 BIOCHEMISTRY SEGMENT TO HOLD LARGEST MARKET SHARE TILL 2030 50
FIGURE 18 HOME CARE SETTINGS AND CLINICAL LABORATORIES TO ACCOUNT FOR MAJOR MARKET SHARES DURING FORECAST PERIOD 51
FIGURE 19 VIETNAM TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 51
FIGURE 20 ASEAN POINT OF CARE DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 52
FIGURE 21 ESTIMATES OF TB INCIDENCE FOR SOUTHEAST ASIA REGION,
BY AGE GROUP AND GENDER (2023) 54
FIGURE 22 ASEAN POINT OF CARE DIAGNOSTICS MARKET: TRENDS/DISRUPTIONS
IMPACTING CUSTOMERS’ BUSINESSES 62
FIGURE 23 ASEAN POINT OF CARE DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS 64
FIGURE 24 ASEAN POINT OF CARE DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS 65
FIGURE 25 ASEAN POINT OF CARE DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS 67
FIGURE 26 INVESTMENT & FUNDING SCENARIO, 2021−2024 68
FIGURE 27 ASEAN POINT OF CARE DIAGNOSTICS MARKET: PATENT ANALYSIS,
JANUARY 2014–DECEMBER 2024 71
FIGURE 28 ASEAN POINT OF CARE DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 82
FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TECHNOLOGY 84
FIGURE 30 KEY BUYING CRITERIA, BY TECHNOLOGY 85
FIGURE 31 ASEAN POINT OF CARE DIAGNOSTICS MARKET: POTENTIAL OF AI 86
FIGURE 32 ASEAN: POINT OF CARE DIAGNOSTICS MARKET SNAPSHOT 170
FIGURE 33 REVENUE ANALYSIS OF KEY PLAYERS IN ASEAN POINT OF CARE
DIAGNOSTICS MARKET, 2022–2024 236
FIGURE 34 MARKET SHARE ANALYSIS OF KEY PLAYERS IN ASEAN POINT OF CARE DIAGNOSTICS MARKET, 2024 237
FIGURE 35 ASEAN POINT OF CARE DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 240
FIGURE 36 ASEAN POINT OF CARE DIAGNOSTICS MARKET: COMPANY FOOTPRINT 241
FIGURE 37 ASEAN POINT OF CARE DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 247
FIGURE 38 EV/EBITDA OF KEY VENDORS, 2025 249
FIGURE 39 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2025 250
FIGURE 40 ASEAN POINT OF CARE DIAGNOSTICS MARKET: BRAND/PRODUCT
COMPARISON MATRIX 250
FIGURE 41 ABBOTT: COMPANY SNAPSHOT (2024) 255
FIGURE 42 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2024) 261
FIGURE 43 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2024) 267
FIGURE 44 SYSMEX CORPORATION: COMPANY SNAPSHOT (2023) 273
FIGURE 45 DANAHER CORPORATION: COMPANY SNAPSHOT (2024) 277
FIGURE 46 BD: COMPANY SNAPSHOT (2024) 281
FIGURE 47 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2024) 284
FIGURE 48 CARDINAL HEALTH: COMPANY SNAPSHOT (2024) 292
FIGURE 49 BIOMÉRIEUX: COMPANY SNAPSHOT (2024) 296
FIGURE 50 EKF DIAGNOSTICS HOLDINGS PLC: COMPANY SNAPSHOT (2023) 300
FIGURE 51 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024) 303
MarketsandMarkets（マーケッツアンドマーケッツ）は広範な市場を対象にした市場調査レポートを出版しています。世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | お問合せください | お問合せください | お問合せください |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- サプライチェーンマネジメント（SCM）市場 – 2030年までの世界予測 2025-07-08
- バイオセンサー市場 – 2030年までの世界予測 2025-07-08
- In situ ハイブリダイゼーション（ISH）市場 – 2030年までの世界予測 2025-07-08
- 燃料電池市場 – 2030年までの世界予測 2025-07-08
- 施設管理市場 – 2030年までの世界予測 2025-07-07